Author: Hu, Aimin; Li, Junyu; Ruan, Shufang; Fan, Ying; Liao, Yuqian
Title: Polymorphisms in CLDN1 are associated with age and differentiation of triple-negative breast cancer patients Document date: 2019_4_23
ID: 106tex7s_12
Snippet: Down-regulation of CLDN1 was associated with shorter DFS of breast cancer patients [9] . In TNBC, CLDN1-negative phenotype also predicted poor prognosis [36, 37] . In our study, no association between polymorphisms in CLDN1 and survival of TNBC patients was observed. There are some explanations. First, the sample size was relatively small and we did not do subgroup analysis. Second, though polymorphisms in CLDN1 might influence the expression lev.....
Document: Down-regulation of CLDN1 was associated with shorter DFS of breast cancer patients [9] . In TNBC, CLDN1-negative phenotype also predicted poor prognosis [36, 37] . In our study, no association between polymorphisms in CLDN1 and survival of TNBC patients was observed. There are some explanations. First, the sample size was relatively small and we did not do subgroup analysis. Second, though polymorphisms in CLDN1 might influence the expression level of CLDN1 protein, the complex interactions between CLDN family members could also affect the results. By using STRING, we found that CLDN1 interacts with some other proteins in CLDN family, such as CLDN2, CLDN3, CLDN6, CLDN12 and so on (Figure 1 ). CLDN 12 expression could be clinically useful for predicting the survival of the ER-negative subgroup of patients with breast cancer [38] . High expression of CLDN6 confers chemoresistance on breast cancer [39] . So, combination analysis of CLDN1 and other related proteins might help us to better understand the role of CLDN1 in TNBC.
Search related documents:
Co phrase search for related documents- complex interaction and high expression: 1, 2, 3
- complex interaction and poor prognosis: 1, 2
- complex interaction and related protein: 1
- expression level and high expression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78
- expression level and poor prognosis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
- expression level and related protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
- expression level and sample size: 1
- expression level and subgroup analysis: 1
- expression level and TNBC CLDN1 role: 1
- high expression and poor prognosis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47
- high expression and related protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- high expression and result affect: 1
- high expression and sample size: 1, 2
- high expression and subgroup analysis: 1, 2
- high expression and TNBC CLDN1 role: 1
- poor prognosis and related protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- poor prognosis and sample size: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- poor prognosis and subgroup analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- sample size and subgroup analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42
Co phrase search for related documents, hyperlinks ordered by date